Wedbush Lifts Earnings Estimates for Bicara Therapeutics

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Wedbush upped their FY2028 earnings per share estimates for shares of Bicara Therapeutics in a report released on Sunday, April 27th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($2.06) for the year, up from their previous estimate of ($2.17). Wedbush has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

BCAX has been the subject of a number of other research reports. HC Wainwright decreased their target price on Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wells Fargo & Company assumed coverage on shares of Bicara Therapeutics in a research report on Thursday, April 17th. They set an “underweight” rating and a $8.00 price target for the company. Finally, Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.43.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $14.37 on Wednesday. Bicara Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $28.09. The business has a 50-day simple moving average of $12.87 and a two-hundred day simple moving average of $15.99.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Red Tree Management LLC bought a new position in Bicara Therapeutics in the 4th quarter worth approximately $55,230,000. Adage Capital Partners GP L.L.C. boosted its stake in Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock worth $37,893,000 after purchasing an additional 1,375,265 shares during the period. Braidwell LP boosted its stake in Bicara Therapeutics by 20.7% in the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock worth $34,851,000 after purchasing an additional 343,059 shares during the period. Deep Track Capital LP boosted its stake in Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock worth $34,840,000 after purchasing an additional 1,203,148 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Bicara Therapeutics by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,547,180 shares of the company’s stock worth $26,953,000 after purchasing an additional 8,246 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.